CopenFast trial: Faster-acting insulin Fiasp versus insulin NovoRapid in the treatment of women with type 1 or type 2 diabetes during pregnancy and lactation - a randomised controlled trial

INTRODUCTION: Faster-acting insulin aspart (Fiasp) is approved for use in pregnancy and lactation, but no clinical study has evaluated its effects during this life stage in women with pre-existing diabetes. The aim of the CopenFast trial is to evaluate the effect of Fiasp compared with insulin aspar...

Descripción completa

Detalles Bibliográficos
Autores principales: Nørgaard, Sidse Kjærhus, Mathiesen, Elisabeth Reinhardt, Nørgaard, Kirsten, Clausen, Tine Dalsgaard, Damm, Peter, Ringholm, Lene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Diabetes and Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8043014/
https://www.ncbi.nlm.nih.gov/pubmed/33837106
http://dx.doi.org/10.1136/bmjopen-2020-045650

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8043014/
https://www.ncbi.nlm.nih.gov/pubmed/33837106
http://dx.doi.org/10.1136/bmjopen-2020-045650

Ejemplares similares